Dr. Brad Thompson reports

ONCOLYTICS BIOTECH ANNOUNCES APPOINTMENT OF DR. GEORGE M. GILL AS CHIEF MEDICAL OFFICER

Oncolytics Biotech Inc. has appointed George M. Gill, MD, as chief medical officer. He has been senior vice-president of clinical safety and regulatory affairs and an officer of Oncolytics since 2002.

"Dr. Gill has an outstanding track record, having supported the advancement of more than 20 products -- including 11 anti-cancer agents -- through the clinical research and regulatory approval process in the United States, Canada and Europe," said Dr. Brad Thompson, president and chief executive officer of Oncolytics. "With his added responsibilities, Dr. Gill will continue to play a pivotal role in advancing our proprietary product, Reolysin, through the clinical and regulatory processes."

Prior to joining Oncolytics, Dr. Gill was vice-president of clinical research and vice-president of medical affairs at Ligand Pharmaceuticals, senior director and head of United States clinical and medical affairs for ICI Pharmaceuticals (now AstraZeneca), and vice-president and head of worldwide regulatory affairs for the Bristol-Myers Co. (now Bristol-Myers Squibb). Dr. Gill began his career in the industry at Hoffman-La Roche, where he held several clinical and regulatory positions, including director of the clinical oncology group and associate director of the regulatory affairs department. Dr. Gill holds a BSc (chemistry) from Dickinson College in Pennsylvania and an MD from the school of medicine of the University of Pennsylvania. He is board certified in pediatrics.

We seek Safe Harbor.